Top

BioDrugs

Published in:

01-08-2010 | Review Article

CpG Oligodeoxynucleotides as TLR9 Agonists

Therapeutic Application in Allergy and Asthma

Authors: Gaurav K. Gupta, Dr Devendra K. Agrawal

Published in: BioDrugs | Issue 4/2010

Abstract

Unmethylated cytosine-phosphate-guanine (CpG) dinucleotides in microbial DNA sequences activate Toll-like receptor (TLR) 9, and previous studies have shown that oligodeoxynucleotides (ODNs) containing CpG in specific base sequence motifs (CpG ODNs) can reiterate the majority of the immunomodulatory effects produced by bacterial DNA. Many of the manifestations in allergic diseases are primarily due to T helper (T_h)-2 cell-type responses. CpG ODNs can induce T_h1 and T-regulatory (T_reg) cell-type cytokines that can suppress the T_h2 response. The therapeutic application of TLR9 has been explored extensively in recent years, and many studies are being conducted to assess the safety and efficacy of TLR9 agonists in various diseases, including atopic and infectious diseases, and cancer. Studies in murine models have shown that the development of atopic airway disease can be prevented by treatment with CpG ODNs. Various clinical trials are currently ongoing to determine the efficacy of CpG ODNs as a therapeutic tool for atopic diseases. In this review, we discuss the therapeutic application of CpG ODNs in allergy and asthma. CpG ODNs may be used alone or as an adjuvant to immunotherapy to treat these disorders.

Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21: 335–76PubMedCrossRef

Peter M, Bode K, Lipford GB, et al. Characterization of suppressive oligodeoxynucleotides that inhibit Toll-like receptor-9-mediated activation of innate immunity. Immunology 2008 Jan; 123(1): 118–28PubMedCrossRef

Krieg AM. Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim Biophys Acta 1999 Dec 10; 1489(1): 107–16PubMedCrossRef

Kuramoto E, Yano O, Kimura Y, et al. Oligonucleotide sequences required for natural killer cell activation. Jpn J Cancer Res 1992 Nov; 83(11): 1128–31PubMedCrossRef

Agrawal S, Kandimalla ER. Modulation of Toll-like receptor 9 responses through synthetic immunostimulatory motifs of DNA. Ann N Y Acad Sci 2003 Dec; 1002: 30–42PubMedCrossRef

Agrawal S, Kandimalla ER. Antisense therapeutics: is it as simple as complementary base recognition? Mol Med Today 2000 Feb; 6(2): 72–81PubMedCrossRef

Lewis EJ, Agrawal S, Bishop J, et al. Non-specific antiviral activity of antisense molecules targeted to the E1 region of human papillomavirus. Antiviral Res 2000 Dec; 48(3): 187–96PubMedCrossRef

Dalpke A, Zimmermann S, Heeg K. CpG DNA in the prevention and treatment of infections. Biodrugs 2002; 16(6): 419–31PubMedCrossRef

Bhagat L, Zhu FG, Yu D, et al. CpG penta- and hexadeoxyribonucleotides as potent immunomodulatory agents. Biochem Biophys Res Commun 2003 Jan 24; 300(4): 853–61PubMedCrossRef

10.

Kandimalla ER, Yu D, Zhao Q, et al. Effect of chemical modifications of cytosine and guanine in a CpG-motif of oligonucleotides: structure-immunostimulatory activity relationships. Bioorg Med Chem 2001 Mar; 9(3): 807–13PubMedCrossRef

11.

Leonard P, Sur S. Interleukin-12: potential role in asthma therapy. Biodrugs 2003; 17(1): 1–7PubMedCrossRef

12.

Jain VV, Kitagaki K, Businga T, et al. CpG-oligodeoxynucleotides inhibit airway remodeling in a murine model of chronic asthma. J Allergy Clin Immunol 2002 Dec; 110(6): 867–72PubMedCrossRef

13.

Uematsu S, Akira S. Toll-like receptors and type I interferons. J Biol Chem 2007 May 25; 282(21): 15319–23PubMedCrossRef

14.

Medzhitov R, Preston-Hurlburt P, Janeway Jr CA. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997 Jul 24; 388(6640): 394–7PubMedCrossRef

15.

Takeuchi O, Kawai T, Sanjo H, et al. TLR6: a novel member of an expanding Toll-like receptor family. Gene 1999 Apr 29; 231(1–2): 59–65PubMedCrossRef

16.

Du X, Poltorak A, Wei Y, et al. Three novel mammalian toll-like receptors: gene structure, expression, and evolution. Eur Cytokine Netw 2000 Sep; 11(3): 362–71PubMed

17.

Seya T, Funami K, Taniguchi M, et al. Antibodies against human Toll-like receptors (TLRs): TLR distribution and localization in human dendritic cells. J Endotoxin Res 2005; 11(6): 369–74PubMed

18.

Muzio M, Bosisio D, Polentarutti N, et al. Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J Immunol 2000 Jun 1; 164(11): 5998–6004PubMed

19.

Kadowaki N, Ho S, Antonenko S, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 2001 Sep 17; 194(6): 863–9PubMedCrossRef

20.

Krug A, Towarowski A, Britsch S, et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol 2001 Oct; 31(10): 3026–37PubMedCrossRef

21.

Rissoan MC, Soumelis V, Kadowaki N, et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999 Feb 19; 283(5405): 1183–6PubMedCrossRef

22.

Liu YJ. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 2001 Aug 10; 106(3): 259–62PubMedCrossRef

23.

Liu YJ, Kanzler H, Soumelis V, et al. Dendritic cell lineage, plasticity and cross-regulation. Nat Immunol 2001 Jul; 2(7): 585–9PubMedCrossRef

24.

Kline JN, Waldschmidt TJ, Businga TR, et al. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J Immunol 1998; 160: 2555–9PubMed

25.

Jarrossay D, Napolitani G, Colonna M, et al. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol 2001 Nov; 31(11): 3388–93PubMedCrossRef

26.

Ito T, Amakawa R, Kaisho T, et al. Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J Exp Med 2002 Jun 3; 195(11): 1507–12PubMedCrossRef

27.

Latz E, Schoenemeyer A, Visintin A, et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 2004 Feb; 5(2): 190–8PubMedCrossRef

28.

Rutz M, Metzger J, Gellert T, et al. Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur J Immunol 2004 Sep; 34(9): 2541–50PubMedCrossRef

29.

Jain VV, Kitagaki K, Kline JN. CpG DNA and immunotherapy of allergic airway diseases. Clin Exp Allergy 2003 Oct; 33(10): 1330–5PubMedCrossRef

30.

Krishnan J, Lee G, Choi S. Drugs targeting Toll-like receptors. Arch Pharm Res 2009 Nov; 32(11): 1485–502PubMedCrossRef

31.

Ahmad-Nejad P, Hacker H, Rutz M, et al. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol 2002 Jul; 32(7): 1958–68PubMedCrossRef

32.

Broide D, Schwarze J, Tighe H, et al. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. J Immunol 1998 Dec 15; 161(12): 7054–62PubMed

33.

Yi AK, Tuetken R, Redford T, et al. CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species. J Immunol 1998 May 15; 160(10): 4755–61PubMed

34.

Peter ME, Kubarenko AV, Weber AN, et al. Identification of an N-terminal recognition site in TLR9 that contributes to CpG-DNA-mediated receptor activation. J Immunol 2009 Jun 15; 182(12): 7690–7PubMedCrossRef

35.

Fonseca DE, Kline JN. Use of CpG oligonucleotides in treatment of asthma and allergic disease. Adv Drug Deliv Rev 2009 Mar 28; 61(3): 256–62PubMedCrossRef

36.

Kline JN, Krieg AM. Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy. Drug News Perspect 2008 Oct; 21(8): 434–9PubMed

37.

Hurtado P, Peh CA. LL-37 promotes rapid sensing of CpG oligodeoxynucleotides by B lymphocytes and plasmacytoid dendritic cells. J Immunol 2010 Feb 1; 184(3): 1425–35PubMedCrossRef

38.

Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000 Dec 7; 408(6813): 740–5PubMedCrossRef

39.

Vollmer J, Weeratna R, Payette P, et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 2004 Jan; 34(1): 251–62PubMedCrossRef

40.

Kitagaki K, Jain VV, Businga TR, et al. Immunomodulatory effects of CpG oligodeoxynucleotides on established th2 responses. Clin Diagn Lab Immunol 2002 Nov; 9(6): 1260–9PubMed

41.

Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clone: I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986 Apr 1; 136(7): 2348–57PubMed

42.

Gavett SH, Chen X, Finkelman F, et al. Depletion of murine CD4+ T lymphocytes prevents antigen-induced airway hyperreactivity and pulmonary eosinophilia. Am J Respir Cell Mol Biol 1994 Jun; 10(6): 587–93PubMed

43.

Hirota K, Martin B, Veldhoen M. Development, regulation and functional capacities of Th17 cells. Semin Immunopathol 2010 Mar; 32(1): 3–16PubMedCrossRef

44.

Zhao Y, Yang J, Gao YD, et al. Th17 immunity in patients with allergic asthma. Int Arch Allergy Immunol 2009 Oct 21; 151(4): 297–307PubMedCrossRef

45.

Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005 Nov; 6(11): 1123–32PubMedCrossRef

46.

Nakae S, Komiyama Y, Nambu A, et al. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 2002 Sep; 17(3): 375–87PubMedCrossRef

47.

Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007 Feb 8; 445(7128): 648–51PubMedCrossRef

48.

Barchet W, Wimmenauer V, Schlee M, et al. Accessing the therapeutic potential of immunostimulatory nucleic acids. Curr Opin Immunol 2008 Aug; 20(4): 389–95PubMedCrossRef

49.

Ishifune C, Maekawa Y, Takayuki Y. Plasmacytoid dendritic cells are crucial for Th17 differentiation [abstract]. J Immunol 2009; 182: 90.14

50.

Postma DS, Kerstjens HA, ten Hacken NH. Inhaled corticosteroids and long-acting beta-agonists in adult asthma: a winning combination in all? Naunyn Schmiedebergs Arch Pharmacol 2008 Aug; 378(2): 203–15PubMedCrossRef

51.

Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med 1995 Apr; 151(4): 969–74PubMed

52.

Creticos PS, Reed CE, Norman PS, et al. Ragweed immunotherapy in adult asthma. New Engl J Med 1996 Feb 22; 334(8): 501–6PubMedCrossRef

53.

Heeg K, Zimmermann S. CpG DNA as a Th1 trigger. Int Arch Allergy Immunol 2000 Feb; 121(2): 87–97PubMedCrossRef

54.

Klinman DM, Yi AK, Beaucage SL, et al. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A 1996 Apr 2; 93(7): 2879–83PubMedCrossRef

55.

Kline JN, Krieg AM, Waldschmidt TJ, et al. CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma. J Allergy Clin Immunol 1999 Dec; 104(6): 1258–64PubMedCrossRef

56.

Brusselle G, Kips J, Joos G, et al. Allergen-induced airway inflammation and bronchial responsiveness in wild-type and interleukin-4-deficient mice. Am J Respir Cell Mol Biol 1995 Mar; 12(3): 254–9PubMed

57.

Foster PS, Hogan SP, Ramsay AJ, et al. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J Exp Med 1996 Jan 1; 183(1): 195–201PubMedCrossRef

58.

Taube C, Duez C, Cui ZH, et al. The role of IL-13 in established allergic airway disease. J Immunol 2002 Dec 1; 169(11): 6482–9PubMed

59.

Serebrisky D, Teper AA, Huang CK, et al. CpG oligodeoxynucleotides can reverse Th2-associated allergic airway responses and alter the B7.1/B7.2 expression in a murine model of asthma. J Immunol 2000 Nov 15; 165(10): 5906–12PubMed

60.

Chen W, Liang X, Peterson AJ, et al. The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol 2008 Oct 15; 181(8): 5396–404PubMed

61.

Odemuyiwa SO, Ghahary A, Li Y, et al. Cutting edge: human eosinophils regulate T cell subset selection through indoleamine 2,3-dioxygenase. J Immunol 2004 Nov 15; 173(10): 5909–13PubMed

62.

Fallarino F, Grohmann U, Hwang KW, et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 2003 Dec; 4(12): 1206–12PubMedCrossRef

63.

Kline JN, Kitagaki K, Businga TR, et al. Treatment of established asthma in a murine model using CpG oligodeoxynucleotides. Am J Physiol Lung Cell Mol Physiol 2002 Jul; 283(1): L170–9PubMed

64.

Hussain I, Jain VV, Kitagaki K, et al. Modulation of murine allergic rhinosinusitis by CpG oligodeoxynucleotides. Laryngoscope 2002 Oct; 112(10): 1819–26PubMedCrossRef

65.

Jain VV, Businga TR, Kitagaki K, et al. Mucosal immunotherapy with CpG oligodeoxynucleotides reverses a murine model of chronic asthma induced by repeated antigen exposure. Am J Physiol Lung Cell Mol Physiol 2003 Nov; 285(5): L1137–46PubMed

66.

Kitagaki K, Businga TR, Kline JN. Oral administration of CpG-ODNs suppresses antigen-induced asthma in mice. Clin Exp Immunol 2006 Feb; 143(2): 249–59PubMedCrossRef

67.

Mousavi T, Salek Moghadam A, Falak R, et al. Co-administration of CpG oligonucleotides and Chenopodium album extract reverse IgG2a/IgG1 ratios and increase IFN-gamma and IL-10 productions in a murine model of asthma. Iran J Allergy Asthma Immunol 2008 Mar; 7(1): 1–6PubMed

68.

Mousavi T, Salek Moghadam A, Falak R. Immunotherapy of Chenopodium album induced asthma by intranasal administration of CpG oligodeoxynucleotides in BALB/c mice. Iran J Immunol 2008 Mar; 5(1): 57–63PubMed

69.

Mousavi T, Tajik N, Moradi M, et al. CpG Immunotherapy in Chenopodium album sensitized mice: the comparison of IFN-gamma, IL-10 and IgE responses in intranasal and subcutaneous administrations [abstract]. Clin Mol Allergy 2008; 6: 10PubMedCrossRef

70.

Martínez Gómez JM, Fischer S, Csaba N, et al. A protective allergy vaccine based on CpG- and protamine-containing PLGA microparticles. Pharm Res 2007 Oct; 24(10): 1927–35PubMedCrossRef

71.

Suzuki M, Ohta N, Min WP, et al. Immunotherapy with CpG DNA conjugated with T-cell epitope peptide of an allergenic Cry j 2 protein is useful for control of allergic conditions in mice. Int Immunopharmacol 2007 Jan; 7(1): 46–54PubMedCrossRef

72.

Marshall JD, Abtahi S, Eiden JJ, et al. Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H)1 cytokine expression while downregulating T(H)2 cytokine expression in PBMCs from human patients with ragweed allergy. J Allergy Clin Immunol 2001 Aug; 108(2): 191–7PubMedCrossRef

73.

Creticos PS, Schroeder JT, Hamilton RG, et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. New Engl J Med 2006 Oct 5; 355(14): 1445–55PubMedCrossRef

74.

Gauvreau GM, Hessel EM, Boulet LP, et al. Immunostimulatory sequences regulate interferon-inducible genes but not allergic airway responses. Am J Respir Crit Care Med 2006 Jul 1; 174(1): 15–20PubMedCrossRef

75.

Senti G, Johansen P, Haug S, et al. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin Exp Allergy 2009 Apr; 39(4): 562–70PubMedCrossRef

76.

Vollmer J, Weeranta R, Payette P, et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 2004; 34: 251–62PubMedCrossRef

77.

Tan L, Rogers TJ, Hatzirodos N, et al. Immunomodulatory effect of cytosine-phosphate-guanosine (CpG)-oligonucleotides in nonasthmatic chronic rhinosinusitis: an explant model. Am J Rhinol Allergy 2009 Mar–Apr; 23(2): 123–9PubMedCrossRef

78.

Tulic MK, Fiset PO, Christodoulopoulos P, et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol 2004 Feb; 113(2): 235–41PubMedCrossRef

79.

Mutwiri G, van Drunen Littel-van den Hurk S, Babiuk LA. Approaches to enhancing immune responses stimulated by CpG oligodeoxynucleotides. Adv Drug Deliv Rev 2009 Mar 28; 61(3): 226–32PubMedCrossRef

80.

Boukhvalova MS, Sotomayor TB, Point RC, et al. Activation of interferon response through Toll-like receptor 3 impacts viral pathogenesis and pulmonary toll-like receptor expression during respiratory syncytial virus and influenza infections in the cotton rat sigmodon hispidus model. J Interferon Cytokine Res. Epub 2009 Dec 28

81.

Knuefermann P, Baumgarten G, Koch A, et al. CpG oligonucleotide activates Toll-like receptor 9 and causes lung inflammation in vivo [abstract]. Respiratory Res 2007; 8: 72CrossRef

82.

Knuefermann P, Schwederski M, Velten M, et al. Bacterial DNA induces myocardial inflammation and reduces cardiomyocyte contractility: role of toll-like receptor 9. Cardiovas Res 2008 Apr 1; 78(1): 26–35CrossRef

83.

Thaxton JE, Romero R, Sharma S. TLR9 activation coupled to IL-10 deficiency induces adverse pregnancy outcomes. J Immunol 2009 Jul 15; 183(2): 1144–54PubMedCrossRef

84.

Huang B, Zhao J, Unkeless JC, et al. TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 2008 Jan 7; 27(2): 218–24PubMedCrossRef

85.

Chiron D, Pellat-Deceunynck C, Maillasson M, et al. Phosphorothioate-modified TLR9 ligands protect cancer cells against TRAIL-induced apoptosis. J Immunol 2009 Oct 1; 183(7): 4371–7PubMedCrossRef

86.

Parkinson T. The future of toll-like receptor therapeutics. Curr Opin Mol Ther 2008 Feb; 10(1): 21–31PubMed

87.

Vollmer J, Krieg AM. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Del Rev 2009 Mar 28; 61(3): 195–204CrossRef

88.

Lahiri A, Das P, Chakravortty D. Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond. Vaccine 2008 Dec 9; 26(52): 6777–83PubMedCrossRef

89.

Booth JS, Buza JJ, Potter A, et al. Co-stimulation with TLR7/8 and TLR9 agonists induce down-regulation of innate immune responses in sheep blood mononuclear and B cells. Dev Comp Immunol 2010 May; 34(5): 572–8PubMedCrossRef

90.

Fanta CH. Asthma. New Engl J Med 2009 Mar 5; 360(10): 1002–14PubMedCrossRef

91.

Bjorksten B, Clayton T, Ellwood P, et al. Worldwide time trends for symptoms of rhinitis and conjunctivitis: phase III of the International Study of Asthma and Allergies in Childhood. Pediatr Allergy Immunol 2008 Mar; 19(2): 110–24PubMedCrossRef

92.

Pearce N, Ait-Khaled N, Beasley R, et al. Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax 2007 Sep; 62(9): 758–66PubMedCrossRef

Title: CpG Oligodeoxynucleotides as TLR9 Agonists
Therapeutic Application in Allergy and Asthma
Authors: Gaurav K. Gupta
Dr Devendra K. Agrawal
Publication date: 01-08-2010
Publisher: Springer International Publishing
Published in: BioDrugs / Issue 4/2010
Print ISSN: 1173-8804
Electronic ISSN: 1179-190X
DOI: https://doi.org/10.2165/11536140-000000000-00000

At a glance: The STEP trials

Springer Medicine

CpG Oligodeoxynucleotides as TLR9 Agonists

Therapeutic Application in Allergy and Asthma

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2010

Relevant Criteria for Selecting an Intravenous Immunoglobulin Preparation for Clinical Use

Stem Cell Therapies to Treat Muscular Dystrophy

Therapeutic Approaches to Multiple Sclerosis

Spotlight on Panitumumab in Metastatic Colorectal Cancer